Results 191 to 200 of about 27,256 (249)

Sitagliptin monotherapy has better effect on insulinogenic index than glimepiride monotherapy in Japanese patients with type 2 diabetes mellitus: a 52-week, multicenter, parallel-group randomized controlled trial [PDF]

, 2016

core   +1 more source

Can DPP-4 Inhibitors Improve Glycemic Control and Preserve Beta-Cell Function in Type 1 Diabetes Mellitus? A Systematic Review. [PDF]

Diseases
Villa Chagas H, Laurindo LF, Dogani Rodrigues V, Haber JFDS, Chagas EFB, Barbalho SM.   +5 more
europepmc   +1 more source

DPP4 inhibitors as a novel therapeutic strategy in colorectal cancer: Integrating network biology and experimental insights. [PDF]

PLoS One
Bardaweel SK, Abu Sneineh B, Hajjo R, Abu Khalaf R.   +3 more
europepmc   +1 more source

BRIDGE-DS study: a multicenter, observational, retrospective analysis of dapagliflozin and sitagliptin combination on modifiable cardiovascular risk factors in T2DM patients with ASCVD or high cardiovascular risk. [PDF]

Cardiovasc Endocrinol Metab
Bhamri N, Kumar A, Mishra C, Devarbhavi PK, Prasad S, Rudach DS, Potdar A, Patil SN, Tewari AK, Jagdish PS, Gayan R, Bansal S, Maheshbabu CR, Asalkar AH, Chitale M, Kesarkar RN, Prasad A, Pednekar A.   +17 more
europepmc   +1 more source

DPP4-inhibition reduces pro-inflammatory cytokine production by alpha-beta and gamma-delta T cells in vitro and in the biliary atresia mouse model. [PDF]

Sci Rep
Wilde AC, Uecker M, Gueler F, Prinz I, Madadi-Sanjani O, Petersen C, Kuebler JF, Klemann C.   +7 more
europepmc   +1 more source

Efficacy and Safety of Vildagliptin Versus Other Dipeptidyl Peptidase 4 (DPP-4) Inhibitors in the Management of Type 2 Diabetes Mellitus: A Systematic Review of Randomized Controlled Trials. [PDF]

Cureus
Selvaraj V.
europepmc   +1 more source

Comparative assessment of treatment outcomes of empagliflozin add-on metformin and sitagliptin add-on metformin therapies in uncontrolled type 2 diabetes mellitus: findings from an observational study in Pakistan. [PDF]

J Health Popul Nutr
Khan AU, Sharif MJH, Ashfaq M, Khan Q, Iqbal MM, Iqbal A, Bashatah A, Syed W, Alqahtani N.   +8 more
europepmc   +1 more source

Dipeptidyl peptidase-4 enzyme inhibition and its impacts on hepatic preneoplasia: a new avenue for liver cancer management. [PDF]

Front Pharmacol
Eitah HE, Sayed RH, Maklad YA, Gamal El Din AA, Mahmoud K, El-Sahar AE, Alhejely A, Abdulbaqi AA, Naeim Attia H.   +8 more
europepmc   +1 more source

SGLT2 Inhibitors and the Risk of Infections in Type 2 Diabetes: Systematic Review and Meta-Analyses of Real-World Evidence. [PDF]

J Diabetes Res
Alfonso Arvez MJ, Tan GSQ, Leung MTY, Ademi Z, Bell JS.   +4 more
europepmc   +1 more source

Comparison of the effects of empagliflozin and sitagliptin, as an add-on to metformin, on cardio-metabolic and glycemic parameters of patients with type 2 diabetes mellitus: a randomized, double-blind clinical trial. [PDF]

BMC Res Notes
Mesri Alamdari N, Barghaman M, Roshanravan N, Mobasseri M, Tutunchi H, Baharami A, Aliasgarzadeh A, Sadra V.   +7 more
europepmc   +1 more source